ATE217889T1 - Humane antikörper gegen faktor ix/ixa - Google Patents

Humane antikörper gegen faktor ix/ixa

Info

Publication number: ATE217889T1
Authority: AT; Austria
Prior art keywords: ixa; fix; human antibodies; antibodies against; against factor
Prior art date: 1998-08-28

Application number

AT99943928T

Other languages

English (en)

Inventor

Camellia W Adams

Brigitte Devaux

Dan L Eaton

Philip E Hass

J Kevin Judice

Daniel Kirchhofer

Shelley Suggett

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-28

Filing date

1999-08-26

Publication date

2002-06-15

1999-08-26 Application filed by Genentech Inc filed Critical Genentech Inc

2002-06-15 Application granted granted Critical

2002-06-15 Publication of ATE217889T1 publication Critical patent/ATE217889T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT99943928T 1998-08-28 1999-08-26 Humane antikörper gegen faktor ix/ixa ATE217889T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9823398P	1998-08-28	1998-08-28
US12276799P	1999-03-03	1999-03-03
PCT/US1999/019453 WO2000012562A1 (en)	1998-08-28	1999-08-26	HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (1)

Publication Number	Publication Date
ATE217889T1 true ATE217889T1 (de)	2002-06-15

Family

ID=26794469

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99943928T ATE217889T1 (de)	1998-08-28	1999-08-26	Humane antikörper gegen faktor ix/ixa

Country Status (15)

Country	Link
US (3)	US6624295B1 (de)
EP (1)	EP1107996B1 (de)
JP (1)	JP4638035B2 (de)
CN (1)	CN1183160C (de)
AT (1)	ATE217889T1 (de)
AU (1)	AU766551C (de)
BR (1)	BR9913435A (de)
CA (1)	CA2341276C (de)
DE (1)	DE69901569T2 (de)
DK (1)	DK1107996T3 (de)
ES (1)	ES2177316T3 (de)
IL (1)	IL140917A0 (de)
NZ (1)	NZ509430A (de)
PT (1)	PT1107996E (de)
WO (1)	WO2000012562A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT411997B (de) *	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) *	2000-03-02	2000-03-02	Protease Ab	Monoclonal antibodies
DE10012732A1 (de) *	2000-03-18	2001-09-20	Aventis Behring Gmbh	Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
CN100339132C (zh) *	2000-05-15	2007-09-26	史密丝克莱恩比彻姆公司	抗血栓剂
GB2378949B (en) *	2001-08-16	2005-09-07	Morten Steen Hanefeld Dziegiel	Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de)	2003-03-14	2004-09-30	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper
GB0309126D0 (en) *	2003-04-17	2003-05-28	Neutec Pharma Plc	Clostridium difficile focussed antibodies
EP1531162A1 (de) *	2003-11-14	2005-05-18	Heinz Vollmers	Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de)	2003-11-14	2005-06-16	Müller-Hermelink, Hans Konrad, Prof. Dr.	Humaner monoklonaler Antikörper mit fettsenkender Wirkung
GB0414886D0 (en)	2004-07-02	2004-08-04	Neutec Pharma Plc	Treatment of bacterial infections
DK1905839T4 (da) *	2006-09-22	2019-10-07	Wacker Chemie Ag	Fremgangsmåde til fermentativ fremstilling af proteiner
WO2010045388A2 (en) *	2008-10-14	2010-04-22	Dyax Corp.	Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
AU2011234521B2 (en) *	2010-03-30	2015-04-23	Octapharma Ag	A process for purifying Vitamin K dependent proteins such as coagulation factor IX
WO2011121031A1 (en)	2010-03-30	2011-10-06	Octapharma Ag	Process for the purification of a growth factor protein
CA2796010C (en) *	2010-04-13	2020-05-12	Medimmune, Llc	Trail r2-specific multimeric scaffolds
WO2012161226A1 (ja) *	2011-05-23	2012-11-29	積水メディカル株式会社	Pivka-ii測定試薬における非特異反応の抑制方法
US9623118B2 (en) *	2015-09-01	2017-04-18	Immunwork Inc.	Multi-arm linker constructs for treating pathological blood clots
US20200231701A1 (en) *	2016-12-23	2020-07-23	Novartis Ag	Methods of treatment with anti-factor xi/xia antibodies
KR20190112747A (ko)	2017-02-01	2019-10-07	노보 노르디스크 에이/에스	응고촉진 항체
US11220554B2 (en)	2018-09-07	2022-01-11	Novo Nordisk A/S	Procoagulant antibodies
CN115448985A (zh) *	2021-06-08	2022-12-09	上海循曜生物科技有限公司	新型抗栓抗体
CN116333145B (zh) *	2023-04-14	2023-11-07	北京基科晟斯医药科技有限公司	结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3720983A1 (de) *	1987-06-25	1989-01-05	Hoechst Ag	Immunometrisches bestimmungsverfahren
WO1991016353A1 (en)	1990-04-23	1991-10-31	Corvas International N.V.	Thrombus-specific antibody derivatives
EP0614984B2 (de)	1993-03-05	2010-11-03	Bayer HealthCare LLC	Humane monoklonale anti-TNF alpha Antikörper
ES2191702T3 (es)	1994-03-17	2003-09-16	Merck Patent Gmbh	Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
MA24512A1 (fr) *	1996-01-17	1998-12-31	Univ Vermont And State Agrienl	Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

1999
- 1999-08-26 DE DE69901569T patent/DE69901569T2/de not_active Expired - Lifetime
- 1999-08-26 AU AU56923/99A patent/AU766551C/en not_active Expired
- 1999-08-26 WO PCT/US1999/019453 patent/WO2000012562A1/en not_active Ceased
- 1999-08-26 AT AT99943928T patent/ATE217889T1/de active
- 1999-08-26 IL IL14091799A patent/IL140917A0/xx not_active IP Right Cessation
- 1999-08-26 DK DK99943928T patent/DK1107996T3/da active
- 1999-08-26 CA CA002341276A patent/CA2341276C/en not_active Expired - Lifetime
- 1999-08-26 NZ NZ509430A patent/NZ509430A/en not_active IP Right Cessation
- 1999-08-26 JP JP2000567575A patent/JP4638035B2/ja not_active Expired - Lifetime
- 1999-08-26 CN CNB998100838A patent/CN1183160C/zh not_active Expired - Lifetime
- 1999-08-26 ES ES99943928T patent/ES2177316T3/es not_active Expired - Lifetime
- 1999-08-26 EP EP99943928A patent/EP1107996B1/de not_active Expired - Lifetime
- 1999-08-26 US US09/383,667 patent/US6624295B1/en not_active Expired - Lifetime
- 1999-08-26 PT PT99943928T patent/PT1107996E/pt unknown
- 1999-08-26 BR BR9913435-7A patent/BR9913435A/pt not_active IP Right Cessation
2003
- 2003-07-08 US US10/614,959 patent/US7049411B2/en not_active Expired - Lifetime
2006
- 2006-03-31 US US11/396,115 patent/US7354585B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4638035B2 (ja)	2011-02-23
US7049411B2 (en)	2006-05-23
US6624295B1 (en)	2003-09-23
EP1107996B1 (de)	2002-05-22
WO2000012562A1 (en)	2000-03-09
US20060088534A1 (en)	2006-04-27
AU766551B2 (en)	2003-10-16
DK1107996T3 (da)	2002-09-16
EP1107996A1 (de)	2001-06-20
CN1183160C (zh)	2005-01-05
AU766551C (en)	2005-02-17
NZ509430A (en)	2002-04-26
AU5692399A (en)	2000-03-21
PT1107996E (pt)	2002-10-31
US20060193851A1 (en)	2006-08-31
CA2341276A1 (en)	2000-03-09
IL140917A0 (en)	2002-02-10
CA2341276C (en)	2005-10-11
ES2177316T3 (es)	2002-12-01
US7354585B2 (en)	2008-04-08
JP2002523081A (ja)	2002-07-30
DE69901569T2 (de)	2002-12-19
CN1317015A (zh)	2001-10-10
DE69901569D1 (de)	2002-06-27
BR9913435A (pt)	2001-09-25

Publication	Publication Date	Title
DE69901569D1 (de)	2002-06-27	Humane antikörper gegen faktor ix/ixa
ATE304358T1 (de)	2005-09-15	(s,s)-reboxetin zur behandlung von migränekopfschmerzen
ATA157699A (de)	2004-01-15	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
BR0116452A (pt)	2003-09-30	Composto, composição farmacêutica, uso de um composto
MEP8209A (en)	2011-12-20	Modified factor viii
CY1109984T1 (el)	2014-09-10	Παραλλαγες gla πεδιου παραγοντα vii ή viia
DE50010115D1 (de)	2005-05-25	Zusammensetzung und verfahren zur entkeimung von luft
BRPI0413022A (pt)	2006-10-03	derivados de 3-amino cromado e 2-amino tetralina
ATE376026T1 (de)	2007-11-15	Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
DK1053256T3 (da)	2011-10-03	Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
TNSN05254A1 (en)	2007-07-10	Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
DK1200418T3 (da)	2004-07-26	Nematodicide trifluorbutener
BR0208741A (pt)	2004-06-22	Derivados de piperidina
BR0107691A (pt)	2005-03-22	Sapogeninas substituìdas e seu uso
ATE273690T1 (de)	2004-09-15	Zusammensetzung zur hautdesinfizierung
CY1109995T1 (el)	2014-09-10	Συνθεσεις περιεχουσες προϊοντα σογιας
SE0003476D0 (sv)	2000-09-28	Compounds
TR200001102T2 (tr)	2000-08-21	İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
TR200402070T4 (tr)	2004-09-21	Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
IL144199A0 (en)	2002-05-23	Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ATE386525T1 (de)	2008-03-15	3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
ID25478A (id)	2000-10-05	Agonis 5-ht1f
BR0111785A (pt)	2003-05-20	Composições e métodos para tratamento de candidìase
BRPI0410026A (pt)	2006-04-25	derivados de 3-amino-croman quinolina
ID27656A (id)	2001-04-19	Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya